These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 25529740

  • 1. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
    An XD, Liu H, Xu ZL, Jin Y, Peng X, Yao YM, Geng M, Long YQ.
    Bioorg Med Chem Lett; 2015 Feb 01; 25(3):708-16. PubMed ID: 25529740
    [Abstract] [Full Text] [Related]

  • 2. Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
    Wang Y, Xu ZL, Ai J, Peng X, Lin JP, Ji YC, Geng MY, Long YQ.
    Org Biomol Chem; 2013 Mar 07; 11(9):1545-62. PubMed ID: 23188156
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
    Chen D, Wang Y, Ma Y, Xiong B, Ai J, Chen Y, Geng M, Shen J.
    ChemMedChem; 2012 Jun 07; 7(6):1057-70. PubMed ID: 22581753
    [Abstract] [Full Text] [Related]

  • 4. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7686-98. PubMed ID: 24216091
    [Abstract] [Full Text] [Related]

  • 5. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
    Liu TC, Peng X, Ma YC, Ji YC, Chen DQ, Zheng MY, Zhao DM, Cheng MS, Geng MY, Shen JK, Ai J, Xiong B.
    Acta Pharmacol Sin; 2016 May 15; 37(5):698-707. PubMed ID: 27041462
    [Abstract] [Full Text] [Related]

  • 6. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.
    Kang ST, Kim EY, Achary R, Jung H, Park CH, Yun CS, Hwang JY, Choi SU, Chae C, Lee CO, Kim HR, Ha JD, Ryu D, Cho SY.
    Bioorg Med Chem Lett; 2014 Nov 01; 24(21):5093-7. PubMed ID: 25282552
    [Abstract] [Full Text] [Related]

  • 7. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Yang Y, Zhang Y, Yang L, Zhao L, Si L, Zhang H, Liu Q, Zhou J.
    Bioorg Chem; 2017 Feb 01; 70():126-132. PubMed ID: 28043720
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
    She N, Zhuo L, Jiang W, Zhu X, Wang J, Ming Z, Zhao X, Cong X, Huang W.
    Bioorg Med Chem Lett; 2014 Aug 01; 24(15):3351-5. PubMed ID: 24951334
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Zhang D, Zhang X, Ai J, Zhai Y, Liang Z, Wang Y, Chen Y, Li C, Zhao F, Jiang H, Geng M, Luo C, Liu H.
    Bioorg Med Chem; 2013 Nov 01; 21(21):6804-20. PubMed ID: 23993328
    [Abstract] [Full Text] [Related]

  • 10. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
    Zhou S, Liao H, Liu M, Feng G, Fu B, Li R, Cheng M, Zhao Y, Gong P.
    Bioorg Med Chem; 2014 Nov 15; 22(22):6438-52. PubMed ID: 25438768
    [Abstract] [Full Text] [Related]

  • 11. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
    Damghani T, Moosavi F, Khoshneviszadeh M, Mortazavi M, Pirhadi S, Kayani Z, Saso L, Edraki N, Firuzi O.
    Sci Rep; 2021 Feb 11; 11(1):3644. PubMed ID: 33574356
    [Abstract] [Full Text] [Related]

  • 12. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.
    Park BS, Al-Sanea MM, Abdelazem AZ, Park HM, Roh EJ, Park HM, Yoo KH, Sim T, Tae JS, Lee SH.
    Bioorg Med Chem; 2014 Aug 01; 22(15):3871-8. PubMed ID: 24997577
    [Abstract] [Full Text] [Related]

  • 13. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
    Qi B, Mi B, Zhai X, Xu Z, Zhang X, Tian Z, Gong P.
    Bioorg Med Chem; 2013 Sep 01; 21(17):5246-60. PubMed ID: 23838381
    [Abstract] [Full Text] [Related]

  • 14. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
    Zhang L, Zhang B, Zhao J, Zhi Y, Wang L, Lu T, Chen Y.
    Eur J Med Chem; 2017 Sep 29; 138():942-951. PubMed ID: 28755635
    [Abstract] [Full Text] [Related]

  • 15. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
    Tang Q, Zhang G, Du X, Zhu W, Li R, Lin H, Li P, Cheng M, Gong P, Zhao Y.
    Bioorg Med Chem; 2014 Feb 15; 22(4):1236-49. PubMed ID: 24485123
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
    Liu N, Wang Y, Huang G, Ji C, Fan W, Li H, Cheng Y, Tian H.
    Bioorg Chem; 2016 Apr 15; 65():146-58. PubMed ID: 26950400
    [Abstract] [Full Text] [Related]

  • 17. Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
    Jiang X, Liu H, Song Z, Peng X, Ji Y, Yao Q, Geng M, Ai J, Zhang A.
    Bioorg Med Chem; 2015 Feb 01; 23(3):564-78. PubMed ID: 25537530
    [Abstract] [Full Text] [Related]

  • 18. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D, Ai J, Liang Z, Li C, Peng X, Ji Y, Jiang H, Geng M, Luo C, Liu H.
    Bioorg Med Chem; 2012 Sep 01; 20(17):5169-80. PubMed ID: 22863529
    [Abstract] [Full Text] [Related]

  • 19. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F, Zhang J, Zhang L, Hao Y, Shi C, Xia G, Yu J, Liu Y.
    Bioorg Med Chem; 2016 Sep 15; 24(18):4281-4290. PubMed ID: 27448775
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
    Trani G, Barker JJ, Bromidge SM, Brookfield FA, Burch JD, Chen Y, Eigenbrot C, Heifetz A, Ismaili MHA, Johnson A, Krülle TM, MacKinnon CH, Maghames R, McEwan PA, Montalbetti CAGN, Ortwine DF, Pérez-Fuertes Y, Vaidya DG, Wang X, Zarrin AA, Pei Z.
    Bioorg Med Chem Lett; 2014 Dec 15; 24(24):5818-5823. PubMed ID: 25455497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.